Shots:

• The approval is based on P-II CITN-09/KEYNOTE-017 study assessing Keytruda in 50 patients with recurrent LA or mMCC who had not received prior systemic therapy
• P-II CITN-09/KEYNOTE-017 study results: ORR 56%; CR 24%; PR 32%; DOR @6 mos./ 12 mos. (96%- 54%); median duration of exposure 6.6 mos.
• Keytruda (pembrolizumab) 100mg IV is a mAb- used as an anti-D-L1 therapy that blocks interaction between PD-1 and its ligands i.e PD-L1 & PD- L2- further activating T lymphocytes

Ref: Merck & Co | Image: Merck